Abalos Therapeutics
Essen
About Abalos Therapeutics
The company intends to use the funds to advance its arenavirus-based lead candidates towards clinical testing. They will develop the initial product candidates using its proprietary Fast Evolution platform, which will generate virus strains with optimized anti-tumoral properties. These candidates will be selected based on their ability to re-program the immune system to specifically and efficiently eliminate the malignant tumor tissue.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $49.2M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2021)
- Website: abalos-tx.com
- Phone: +49 201 565 787-00
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/abalos-therapeutics-86726 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.